Telomir Pharmaceuticals, Inc. Common Stock (TELO) Form 4 Telomir Pharmaceuticals / Brian Patrick McNulty ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Bay Shore Trust

(Last) (First) (Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

TAMPA FL 33606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Telomir Pharmaceuticals, Inc. [ TELO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2024		P		49,000	A	$7	5,455,431	I	By Trust(1)
Common Stock	02/13/2024		P		40,000	A	$7	1,365,646	I	See Footnote(2)
Common Stock	02/13/2024		P		49,000	A	$7	1,902,659	I	By Trust(3)
Common Stock								24,391	D(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to buy)	$3.73							06/15/2023	06/15/2028	Common Stock	2,439,025		2,439,025	I	By Trust(1)

1. Name and Address of Reporting Person^*

Bay Shore Trust

(Last) (First) (Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

TAMPA FL 33606

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

McNulty Brian Patrick

(Last) (First) (Middle)

C/O TELOMIR PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

TAMPA FL 33606

(City) (State) (Zip)

Explanation of Responses:

1. These securities are owned directly by the Bay Shore Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Brian McNulty ("Mr. McNulty") as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

2. These securities are owned directly by the MIRALOGX, LLC, of which the Trust holds all of the membership interests, and indirectly by Mr. McNulty as trustee of the Trust. Mr. McNulty disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

3. These securities are owned directly by a trust for which Mr. McNulty serves as trustee. Mr. McNulty disclaims beneficial ownership of the reported securities because he is deemed to hold these securities only because of his role as Trustee and does not have any pecuniary interest in such securities.

4. These securities are owned directly by Mr. McNulty.

	/s/ Nathen Fuentes, Attorney-in-Fact for Brian McNulty, Trustee	02/15/2024
	/s/ Nathen Fuentes, Attorney-in-Fact for Brian McNulty	02/15/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.